Table 7.
Comparison of various reports on the efficacy of PRRT in PGL/PCC patients
| Author and year | Patient number | PR | SD | PD | Death | Follow-up (median, months) | Median OS (months) | Median PFS (months) | TTP |
|---|---|---|---|---|---|---|---|---|---|
| van Essen et al. 2006 [27] | 12 | 2 (17%) | 6 (50%) | 4 (33%) | 2 (16%) | 13 (4–30) | – | – | – |
| Forrer et al. 2008 [16] | 25 | 2PR + 5MR (28%) | 13 (52%) Mixed response 2 (8%) | 6 (24%) | – | *19 (6–50) | – | – | 3 to > 42 Mean not reached |
| Zovato et al. 2012 [28] | 4 | 2 (50%) | 2 (50%) | 0 | 0 | *15.8 (12–25) | – | – | – |
| Pinato et al. 2016 [29] | 5 | 1 (20%) | 3 (60%) | 1 (20%) | 2 (40%) | 13 | – | 17 (0–78) | Not reached |
| Kong et al. 2017 [18] | 20 | CT scan | 5 (25%) | 28 | Not reached | 39 | – | ||
| 29% SSTR | 50% | 14% | |||||||
| 47% | 41% | 12% | |||||||
| Present study | 25 | 5 (20%) | 16 (64%) | 4 (16%) | 7 (28%) | 30 (9–60) | Not reached | 32 | 13 |
PR partial response, SD stable disease, PD progressive disease, OS overall survival, PFS progression-free survival, TTP time to progression, MR minimal response, CT scan computed tomography scan, SSTR imaging somatostatin receptor imaging
*Mean follow-up duration in months